Beijing Biostar Pharmaceuticals Co Ltd
HKEX:2563
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (37.1), the stock would be worth HK$0 (100% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | HK$4.4 |
0%
|
| Industry Average | 37.1 | HK$0 |
-100%
|
| Country Average | 26.4 | HK$0 |
-100%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
B
|
Beijing Biostar Pharmaceuticals Co Ltd
HKEX:2563
|
1.6B HKD | 0 | 0 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | -38 725.3 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 15.5 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.9B USD | -88 198.6 | 38 368.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
59.7B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 69.7 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.5B USD | 45.4 | -3 256.9 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 4.9 | 6.9 |
Market Distribution
Other Multiples
Beijing Biostar Pharmaceuticals Co Ltd
Glance View
Nestled amidst the bustling landscape of China's pharmaceutical industry, Beijing Biostar Pharmaceuticals Co Ltd has carved out a niche by merging traditional Chinese medicine with modern biotechnology. Founded with a vision to revolutionize healthcare, Biostar blends age-old herbal practices with cutting-edge research, producing a diverse range of health products. It positions itself uniquely by focusing on high-quality, innovative treatments that cater to an aging population seeking alternative therapies. The company thrives on its state-of-the-art research facilities and a team of dedicated scientists who constantly evolve and refine their product offerings. This strategy not only helps in preserving traditional knowledge but also enhances market appeal among a growing base of health-conscious consumers. Revenue generation at Beijing Biostar Pharmaceuticals follows a multifaceted approach. The company capitalizes on its extensive product line, which includes everything from dietary supplements to therapeutic pharmaceutical products. Robust manufacturing capabilities allow it to control the production process, ensuring quality and efficiency. Furthermore, Biostar leverages an expansive distribution network, both domestically and overseas, to broaden its market reach. Strategic partnerships with hospitals and clinics further bolster its sales channels, providing a steady flow of income. The company's commitment to research and development is mirrored in its collaboration with academic institutions, fostering innovation and securing intellectual property that promises sustainable growth in a competitive market.